WARRANT AGREEMENTWarrant Agreement • June 18th, 2019 • SELLAS Life Sciences Group, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 18th, 2019 Company Industry JurisdictionThis Warrant Agreement made as of June 18, 2019 (the “Issuance Date”), between SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), Computershare Inc., a Delaware corporation (“Computershare”), and its wholly-owned subsidiary, Computershare Trust Company, N.A., a federally chartered trust company (and together with Computershare, the “Warrant Agent”).
SELLAS Life Sciences Group, Inc. 26,367,200 Shares Common Stock ($0.0001 par value per share) and Pre-Funded Warrants to Purchase up to 73,632,800 Shares of Common Stock and Warrants to Purchase up to 100,000,000 Shares of Common Stock Underwriting...Underwriting Agreement • June 18th, 2019 • SELLAS Life Sciences Group, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 18th, 2019 Company Industry JurisdictionSELLAS Life Sciences Group, Inc., a corporation organized under the laws of Delaware (including any predecessor entities, the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representative”) are acting as Representative, (i) an aggregate of 26,367,200 shares of common stock, $0.0001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Firm Shares”), (ii) pre-funded warrants to purchase up to an aggregate of 73,632,800 shares of Common Stock (the “Pre-Funded Warrants”) at an exercise price of $0.0001 per share and (iii) warrants of the Company to purchase up to an aggregate of 100,000,000 shares of Common Stock (the “Firm Common Warrants”) at an exercise price equal to $0.50 per share. The Firm Shares, Pre-Funded Warrants, and the Firm Common Warrants to be sold by the Company are collectively referred to as the “Firm Securities.” Th